A clinical approach to the use of methotrexate for sarcoidosis

Thorax

Volumn 54, Issue 8, 1999, Pages 742-746

  Baughman, Robert P ^a   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PREDNISONE; STEROID;

BLOOD TOXICITY; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TOXICITY; HUMAN; IRIDOCYCLITIS; LIVER TOXICITY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LUNG TOXICITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SPONTANEOUS ABORTION; T LYMPHOCYTE;

EID: 0032780408     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.8.742     Document Type: Review

References (61)

1. 1 Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238-47.
2. 2 Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149:893-8.
3. 3 Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997;111:623-31.
4. 4 Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticostcroids. Sarcoidosis 1998;15:52-8.
5. 5 Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973;107:609-14.
6. 6 Baughman RP, Lower EE, Lynch JP, Treatment modalities for sarcoidosis. Clin Pulmonol Med 1994;1:223-31.
7. 7 Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983;208:525-33.
8. 8 Scadding JG. Prognosis of intrathoracic sarcoidosis in England. BMJ 1961;4:1165-72.
9. 9 Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax 1995;50: 555-9.
10. 10 Raughman RP, Lower EE, Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med 1997;18:853-64.
11. 11 Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis 1997;14: 154-8.
12. 12 Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med 1996;100:423-7.
13. 13 Lower HE, Broderick JP, Brott TG, et al. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med 1997;157:1864-8.
14. 14 Israel HL. The treatment of sarcoidosis. Postgrad Med J 1970;46:537-40.
15. 15 Lynch JPI, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997;155:395-420.
16. 16 Lacher MJ. Spontaneous remission response to methotrexate in sarcoidosis. Ann Intern Med 1968;69:1247-8.
17. 17 James DG, Jones Williams W. Sarcoidosis and other granulomatous disorders. Philadelphia: Saunders, 1985: 148-51.
18. 18 Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986;29:822-31.
19. 19 Anderson PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Ann Intern Med 1985;103: 489-96.
20. 20 Tolman KG, Clegg DO, Lee RG, et al. Methotrexate and the liver. J Rheumatol 1985;12:S29-34.
21. 21 Williams HJ, Wilkens RF, Samuelson CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1985;28: 721-30.
22. 22 Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316-28.
23. 23 Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990;299:153-7.
24. 24 Baughman RP, Lower EE. The effect of corticosteroid or methotrexate therapy on lung lymphocytes and macrophages in sarcoidosis. Am Rev Respir Dis 1990;142:1268-71.
25. 25 Thomas PD, Hunninghake GW Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987;135: 747-60.
26. 26 Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981;305:429-32.
27. 27 Baughman RP, Strohofer SA, Buchsbaum J, et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36-42.
28. 2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993;103:832-8.
29. 29 Pia G, Pascalis L, Aresu G, et al. Evaluation of the efficacy and toxicity of the cyclosporine A-flucortolone-methotrexate combination in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1996;13:146-52.
30. 30 Gedalia A, Molina JF, Ellis GS, et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 1997;130: 25-9.
31. 31 Feagan BG. Methotrexate therapy for chronic sarcoidosis: is the therapeutic index acceptable? J Pediatr 1997;130:3-4.
32. 32 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995;155:846-51.
33. 33 Baughman RP, Lower EE. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 1997;14:121-30.
34. 34 Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985;12:S35-9.
35. 35 Lower EE, Smith JT, Martelo OJ, et al. The anemia of sarcoidosis. Sarcoidosis 1988;5:51-5.
36. 36 Kennedy D, Yamakido M. Hematologic manifestations of sarcoidosis. Semin Respir Med 1992;13:455-8.
37. 37 Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. JAMA 1978;240:43-50.
38. 38 Maycock RL, Bertrand P, Morrison CE. Manifestations of sarcoidosis. Am J Med 1963;35:67-89.
39. 39 Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994;121:833-41.
40. 40 Sostman HD, Matthay RA, Putman GE. Methotrexate-induced pneumonitis. Medicine 1976;55:371-88.
41. 41 Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992;47:628-33.
42. 42 White DA, Rankin JA, Stover DE, et al. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989;139:18-21.
43. 43 Jones G, Mierins E, Karsh J. Memotrexate-induced asthma. Am Rev Respir Dis 1991;143:179-81.
44. 44 Van de Kerkhof PCM, Hoefnagels WHL, van Haelst JGM, et al. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 1985;10:194-200.
45. 45 Knox TA, Kaplan MM, Gelfand JA, et al. Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med 1995;122:592-5.
46. 46 Balin PL, Tindall JP, Roenigk HH, et al. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 1975;232:359-62.
47. 47 Rustin GJS, Rustin F, Dent J, et al. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med 1982;308:473-6.
48. 48 Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate treated psoriatics. Dermatologica 1983;167:260-1.
49. 49 Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 1993;20:1764-8.
50. 50 Baughman RP, Winget DB, Lower EE. Prospective, randomized, double blind trial of methotrexate as a steroid sparing agent for sarcoidosis: analysis of first 25 patients. Am J Respir Crit Care Med 1997;155:A944
51. 51 Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 1977;97:213-6.
52. 52 Fenton DA, Shaw M, Black MN. Invasive nasal sarcoidosis treated with methotrexate. Clin Exp Dermatol 1985;10:279-83.
53. 53 Soriano FG, Caramelli P, Nitrini R, et al. Neurosarcoidosis: therapeutic success with methotrexate. Postgrad Med J 1990;66:142-3.
54. 54 Webster GF, Razsi LK, Sanchez M, et al. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 1991;24:451-4.
55. 55 Chittock DR, Joseph MG, Paterson NA, et al. Necrotizing sarcoid granulomatosis with pleural involvement. Clinical and radiographic features. Chest 1994;106:672-6.
56. 56 Henderson CA, Ilchyshyn A, Curry AR. Laryngeal and cutaneous sarcoidosis treated with methotrexate. J R Soc Med 1994;87:632-3.
57. 57 Rajendran R, Theertham M, Salgia R, et al. Methotrexate in the treatment of cutaneous sarcoidosis. Sarcoidosis 1994;11: S335-8.
58. 58 Lennarson P, Barney NP. Interstitial keratitis as presenting ophthalmic sign of sarcoidosis in a child. J Pediatr Ophthalmol Strabismus 1995 May-Jun 1996;32:194-6.
59. 59 Kaye O, Palazzo E, Grossin M, et al. Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis. Br J Rheumatol 1995;34:642-4.
60. 60 Agbogu BN, Stern BJ, Sewell C, et al. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995;52:875-9.
61. 61 Morishita M, Matsuda R, Satoh S, et al. Prolonged low dose mediotrexate for cardiac sarcoidosis. Am J Respir Crit Care Med 1998;157:A809.